Tempus AI agreed to buy Personalis for $1.5 billion, stepping deeper into minimal residual disease (MRD) testing and expanding its tumor-informed liquid biopsy portfolio. Under the deal terms, Personalis shareholders will receive $16.25 per share, a ~6% premium to the closing price, with expected close in late 2026 or early 2027 subject to approvals. The acquisition builds on a commercial partnership dating to November 2023, when Tempus invested in Personalis and co-commercialized the NeXT Personal MRD test—a whole-genome sequencing-based, tumor-informed assay. Tempus said combining Personalis’ technology with its multimodal data platform and AI capabilities will support biomarker discovery and personalized cancer care. Personalis reported preliminary second-quarter revenue of $22.4 million and delivered 10,384 tests, both indicating accelerating commercial momentum alongside broader insurance coverage. Tempus expects the Personalis test to complement its existing tumor-naive MRD offerings, as the market shifts toward tumor-informed approaches.